Highlights from ACG2024
Focus on Ulcerative Colitis
DAY 3 - Benefit of Upadacitinib Therapy Is Long-Lasting for Individuals With Inflammatory Bowel Disease
Findings from two long-term studies presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania showed that people treated with upadacitinib for Crohn’s Disease (CD) and ulcerative colitis (UC) maintained clinical and endoscopic improvements over several years of maintenance therapy.
October 31, 2024
Read more
DAY 3 - Investigational Therapy Shows Promise in the Treatment of Moderate to Severe Ulcerative Colitis
A monoclonal antibody with a novel mechanism of action may help patients with ulcerative colitis (UC) achieve and maintain clinical remission and endoscopic improvement of disease even when administered in low doses, according to a study presented at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 31, 2024
Read more
DAY 3 - Real World Comparison of Effectiveness, Durability, and Safety of First-Line Advanced Therapies for Ulcerative Proctitis
Ulcerative proctitis, a subtype of ulcerative colitis, is typically treated with topical 5-aminosalicylic acid and steroid therapies. Many patients with refractory ulcerative proctitis require advanced therapies. However, data on the effectiveness of these advanced therapies in ulcerative proctitis patients have been limited, creating a significant knowledge gap in the field.
October 31, 2024
Read more
DAY 3 - Peri-Procedural Risk Stratification and Management in Cirrhosis
Major surgeries in patients with cirrhosis are on the rise. A 2020 analysis of 804 major surgeries in U.S. Veterans with cirrhosis has revealed that high-risk frailty is associated with a 74% increased hazard of postoperative mortality compared to low-risk frailty.
October 31, 2024
Read moreMore Summaries
DAY1 - The Biologic-Experienced Ulcerative Colitis Patient – Continue or Cut?
"1 in 4 patients with ulcerative colitis (UC) will be admitted to the hospital", Kara M. De Felice, MD, Associate Professor of Medicine at the University of Cincinnati, set the stage at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, held in Philadelphia, Pennsylvania, for her discussion on the appropriate therapy advanced candidates versus surgery for a biologic-experienced patient with UC.
October 29, 2024
Read more
DAY 1 - Janus Kinase Inhibitors: a Safe Second-Line Option for People with Ulcerative Colitis
A real-world study comparing second-line biologic therapies showed that Janus kinase (JAK) inhibitors can achieve symptom control with comparable rates of complications and mortality to those of monoclonal antibodies when used to treat moderate to severe ulcerative colitis (UC). Lead author Emily Shu-Yen Chan, MD, MSc, presented the findings in a poster session at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 29, 2024
Read more
DAY 1 - Online Forum for Individuals with Ulcerative Colitis Reveals Shortcomings of Health Insurance Structure
People living with ulcerative colitis (UC) face a myriad of issues related to disease management and health insurance utilization. Among those, overcoming obstacles to treatment approval and the psychological burden of managing a chronic illness emerged as the most prominent concerns across thousands of Reddit discussions, according to findings presented in a poster session at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 29, 2024
Read more
DAY 1 - Extended Induction Treatment with Upadacitinib Improves Outlook for People with Refractory Inflammatory Bowel Disease
Prolonging the upadacitinib induction period or re-escalating the dose may effectively control disease in people with inflammatory bowel disease (IBD) after initial treatment failure, according to a dual-center retrospective analysis featured at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 29, 2024
Read more
DAY 1 - Inflammatory Bowel Disease Subtype May Influence Risk for Atherosclerotic Cardiovascular Disease
People living with Crohn’s disease (CD) may have a more favorable cardiovascular risk profile than those with ulcerative colitis (UC), according to a retrospective study presented Monday at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 29, 2024
Read more
DAY 2 - Infliximab Versus Vedolizumab in Outpatient Treatment of Immune Checkpoint Inhibitor Colitis
Immune checkpoint inhibitors (ICIs) have FDA approval for over 43 indications. However, ICI-induced colitis remains a common and potentially severe immune-related adverse event. While steroids are the recommended first-line therapy, their prolonged use can lead to significant side effects. The optimal management of moderate to severe ICI colitis, particularly the choice between biologic therapies, remains a challenge for clinicians.
October 30, 2024
Read more
DAY 2 - Improving Outcomes for the Hospitalized IBD Patient: Strategies for Optimizing Inpatient Care
"25% of patients with ulcerative colitis may experience severe disease, and around 40% of these acute severe cases may not respond to steroid treatment," stated Dr. Tauseef Ali, Medical Executive Director of the SSM Health Digestive Institute in Edmond, Oklahoma. Speaking at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia, Dr. Ali outlined his approach to managing hospitalized inflammatory bowel disease (IBD) patients, emphasizing a thorough diagnostic work-up, supportive care, dietary guidance, and symptom management.
October 30, 2024
Read more
DAY 2 - Upadacitinib Passes Real-World Test in the Treatment of Acute Severe Ulcerative Colitis
An analysis featured at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania showed that patients treated with upadacitinib for acute severe ulcerative colitis (UC) achieve similar outcomes to those of infliximab users, and may also experience lower rates of severe complications such as colonic perforation.
October 30, 2024
Read more
DAY 2 - Fatigue Limits Quality of Life for Patients with Crohn’s Disease and Ulcerative Colitis
People living with Crohn’s disease (CD) or ulcerative colitis (UC) often experience disease-related fatigue, which affects their work productivity, social interactions, and many other aspects of their lives, according to a study presented at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania.
October 30, 2024
Read more
DAY 2 - Risk for Adverse Cardiovascular Events Is Similar with Janus Kinase Inhibitors and Biologic Therapies for Inflammatory Bowel Disease
An analysis presented at the ACG 2024 Annual Scientific Meeting in Philadelphia, Pennsylvania showed that Janus kinase (JAK) inhibitors do not increase the risk for major adverse cardiovascular events (MACE) compared with biologic therapies in people with inflammatory bowel disease (IBD).
October 30, 2024
Read more
© 2024 Wolters Kluwer. All right reserved.